Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide dose-reduction study in non-transfusion-dependent thalassemia
ChiCTR2000033205Phase 4Recruiting
- Sponsor
- 923rd Hospital of the Joint Logistics Support Force
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thalidomide in Thalassaemia, sponsored by 923rd Hospital of the Joint Logistics Support Force. Primary endpoints: Hemoglobin at Week 24, Hemolysis index and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
thalidomide
03
Conditions
Thalassaemia
Beyond the preview
Go deeper on ChiCTR2000033205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033205.